Case Reports in Oncology

metrics 2024

Catalyzing Advances in Oncology Practice

Introduction

Case Reports in Oncology is a peer-reviewed journal published by KARGER, dedicated to the dissemination of high-quality case studies and clinical reports in the field of oncology. Since its transition to Open Access in 2008, this Swiss-based journal has aimed to broaden the accessibility of key findings to a global audience of researchers, healthcare professionals, and students. The journal is positioned in the Q3 quartile for oncology, indicating its valuable contribution to the field, while also holding a Scopus rank of 294 out of 404 in Medicine, with a percentile of 27%. However, its open access model ensures that even those outside of traditional academic institutions can engage with critical advancements and novel insights from the oncology community. With a publication span extending from 2010 to 2024, Case Reports in Oncology serves as a crucial platform for sharing unique clinical experiences and innovative treatment strategies, ultimately enriching the practice and study of oncology.

Metrics 2024

SCIMAGO Journal Rank0.30
Journal Impact Factor0.70
Journal Impact Factor (5 years)0.80
H-Index26
Journal IF Without Self0.70
Eigen Factor0.00
Normal Eigen Factor0.41
Influence0.23
Immediacy Index0.60
Cited Half Life4.70
Citing Half Life8.80
JCI0.16
Total Documents2120
WOS Total Citations1354
SCIMAGO Total Citations4470
SCIMAGO SELF Citations104
Scopus Journal Rank0.30
Cites / Document (2 Years)0.72
Cites / Document (3 Years)0.80
Cites / Document (4 Years)0.85

Metrics History

Rank 2024

Scopus

Oncology in Medicine
Rank #294/404
Percentile 27.23
Quartile Q3

IF (Web Of Science)

ONCOLOGY
Rank 297/322
Percentile 7.90
Quartile Q4

JCI (Web Of Science)

ONCOLOGY
Rank 297/322
Percentile 7.76
Quartile Q4

Quartile History

Similar Journals

Case Reports in Oncological Medicine

Advancing oncology through shared clinical insights.
Publisher: HINDAWI LTDISSN: 2090-6706Frequency: 1 issue/year

Case Reports in Oncological Medicine is a distinguished open-access journal published by HINDAWI LTD, dedicated to disseminating valuable insights and findings in the field of oncology. Since its inception in 2011, this journal has aimed to provide a unique platform for the publication of detailed case reports that contribute to our understanding of cancer diagnosis, treatment, and management. With a specific focus on sharing clinical experiences and outcomes, it seeks to engage researchers, healthcare professionals, and students who are committed to advancing oncological knowledge and improving patient care. Although coverage in Scopus was discontinued from 2014 to 2017, the journal currently holds a rank of #232/323 in Medicine - Oncology, placing it within the 28th percentile. Researchers interested in making their work accessible can benefit from the journal's open-access model, allowing greater visibility and citation potential within the scientific community. The journal is positioned as an important resource for those looking to stay updated on the latest case studies and innovations in oncological medicine.

Cancer Radiotherapie

Advancing cancer care through innovative radiotherapy research.
Publisher: ELSEVIERISSN: 1278-3218Frequency: 6 issues/year

Cancer Radiotherapie, published by Elsevier, is a respected academic journal dedicated to advancing the field of oncology and radiology through original research and comprehensive reviews. With an ISSN of 1278-3218 and an E-ISSN of 1769-6658, the journal serves as a vital platform for disseminating knowledge and innovation in cancer treatment methodologies, specifically focusing on radiotherapy. As of 2023, it holds a Category Quartile of Q3 in both Oncology and Radiology, Nuclear Medicine and Imaging, reflecting its significance within these domains amidst a competitive landscape. Despite its current rankings—205th out of 333 in Radiology and 269th out of 404 in Oncology—it continuously strives to build a reputable presence with contributions that push the boundaries of cancer therapy. Although open access options are not available, the journal is committed to ensuring that valuable insights reach healthcare professionals and researchers worldwide, contributing to improved patient outcomes and advancements in treatment efficacy.

LEUKEMIA

Advancing the Frontiers of Hematology and Oncology
Publisher: SPRINGERNATUREISSN: 0887-6924Frequency: 12 issues/year

LEUKEMIA, published by SpringerNature, is a premier journal in the field of hematology and oncology, with ISSN 0887-6924 and E-ISSN 1476-5551. Established in 1987, this esteemed publication serves as a critical platform for disseminating groundbreaking research and comprehensive reviews on the pathophysiology, diagnosis, and treatment of leukemia and related hematological disorders. With a distinguished impact, it holds a top-tier status in several categories, including Q1 rankings in Anesthesiology and Pain Medicine, Cancer Research, Hematology, and Oncology for 2023. The journal is globally recognized for its rigorous peer-review process and is highly regarded among academia, evidenced by its impressive Scopus rankings—7th in Hematology and 24th in Oncology. Researchers, clinicians, and students alike will benefit from the rich content that this journal offers, making it an invaluable resource in the fight against leukemia. The main objective of LEUKEMIA is to advance knowledge and encourage further innovations within the field, ensuring that vital insights reach practitioners and researchers around the world.

Current Problems in Cancer: Case Reports

Advancing oncology through shared case insights.
Publisher: ELSEVIERISSN: 2666-6219Frequency: 2 issues/year

Current Problems in Cancer: Case Reports is a prominent scholarly journal published by Elsevier, focusing on critical case reports within the field of oncology. Since its transition to Open Access in 2020, it has enhanced accessibility for researchers and healthcare professionals seeking to share and discuss unique clinical scenarios and insights that advance cancer treatment and patient care. Operating from the United States, this journal aims to address the important and often intricate challenges faced in oncology, facilitating a platform for knowledge exchange and the exploration of new perspectives in cancer management. Despite its current Q4 category ranking in the 2023 oncology category of Scopus with a rank of #359/404, its goal is to enrich the academic discourse by featuring diverse case reports and promoting evidence-based practices. As the journal evolves from 2021 to 2024, it seeks to impact the field by inviting researchers, professionals, and students to contribute their findings, ultimately fostering a collaborative environment for tackling the complexities of cancer.

International Journal of Clinical Oncology

Shaping the Future of Cancer Management
Publisher: SPRINGER JAPAN KKISSN: 1341-9625Frequency: 6 issues/year

International Journal of Clinical Oncology, published by SPRINGER JAPAN KK, is a leading peer-reviewed journal dedicated to advancing research and clinical practices in the fields of oncology, hematology, and surgery. With its impact factor reflecting its significance and reach in the academic community, this journal serves as a solid platform for researchers, professionals, and students to share and disseminate groundbreaking discoveries and methodologies. Notably, it has secured prestigious rankings in the Q1 category in Medicine (miscellaneous) and Surgery, and Q2 in Hematology and Oncology, illustrating its prominent position in the medical literature. The journal's comprehensive scope addresses pivotal clinical issues from 1996 through 2024, further solidifying its relevance in the ever-evolving landscape of cancer research. Despite not offering open access, the depth and quality of research articles ensure that vital information remains accessible to those committed to improving clinical outcomes in oncology. With a focus on innovative treatments and patient care, the International Journal of Clinical Oncology embodies a commitment to fostering excellence in medical research.

Gastrointestinal Tumors

Bridging Knowledge Gaps in Tumor Research
Publisher: KARGERISSN: 2296-3774Frequency: 4 issues/year

Gastrointestinal Tumors is a reputable, peer-reviewed journal dedicated to advancing knowledge in the field of gastrointestinal oncology. Published by KARGER, this journal has been a pivotal platform since its transition to Open Access in 2014, ensuring that research findings are accessible to a global audience of researchers, clinicians, and students engaged in this vital area of study. With an emphasis on innovative research, clinical studies, and comprehensive reviews, Gastrointestinal Tumors aims to bridge gaps in knowledge and foster discussions that will inform and enhance clinical practices. The journal's commitment to excellence reflects the rising importance of gastrointestinal health in medical research, making it an essential resource for anyone seeking to stay at the forefront of this rapidly evolving field. Based in Basel, Switzerland, it is positioned within a strong academic community, and continues to influence the landscape of gastrointestinal cancer research.

Case Reports in Gastrointestinal Medicine

Innovating patient care with critical clinical insights.
Publisher: HINDAWI LTDISSN: 2090-6528Frequency: 1 issue/year

Case Reports in Gastrointestinal Medicine, published by HINDAWI LTD, is a leading open-access journal dedicated to the dissemination of significant findings in the field of gastrointestinal medicine. Established in 2011, this journal champions the accessibility of scholarly work, allowing researchers, professionals, and students to explore vital case studies that enhance clinical understanding and patient care across various gastrointestinal conditions. With an emphasis on innovative practices and advances in treatment, the journal serves as an invaluable resource for those committed to furthering their knowledge and improving outcomes in gastrointestinal health. By promoting the robust sharing of case reports and clinical insights, Case Reports in Gastrointestinal Medicine not only contributes to the academic community but also supports practitioners in their quest for evidence-based practice.

ACG Case Reports Journal

Empowering Clinicians with Evidence-Based Case Studies
Publisher: LIPPINCOTT WILLIAMS & WILKINSISSN: Frequency: 12 issues/year

ACG Case Reports Journal, published by Lippincott Williams & Wilkins, is a pivotal resource in the realm of gastrointestinal medicine and clinical practice. Since its inception in 2014, this open-access journal has dedicated itself to disseminating high-quality case reports that contribute to the evolving understanding of gastrointestinal diseases and their management. With an impressive ranking of #203 out of 529 in the General Medicine category according to Scopus, placing it in the 61st percentile, the journal underscores its significant role in advancing medical knowledge. This accessibility allows researchers, healthcare professionals, and students to engage with groundbreaking case studies, enriching their expertise and promoting informed clinical decision-making. ACG Case Reports Journal aims to foster a collaborative environment where innovative ideas and clinical experiences converge, ultimately enhancing patient care and outcomes in the field of gastroenterology.

Molecular and Clinical Oncology

Innovating cancer care through rigorous research.
Publisher: SPANDIDOS PUBL LTDISSN: 2049-9450Frequency: 12 issues/year

Molecular and Clinical Oncology is a dynamic journal published by SPANDIDOS PUBL LTD, aimed at advancing the understanding of cancer biology and treatment modalities. With an ISSN of 2049-9450 and an E-ISSN of 2049-9469, the journal serves as a critical platform for researchers and clinicians dedicated to uncovering novel insights in molecular oncology and enhancing clinical practices. As a testament to its growing influence, the journal has achieved a Q3 ranking in Oncology and a Q4 ranking in Cancer Research for the year 2023, reflecting its commitment to publishing high-quality research. Although currently not an Open Access publication, the journal offers crucial subscription options, ensuring comprehensive access to groundbreaking studies and innovations in the field. With converged years spanning 2018 to 2024, the journal is set to continue enriching the academic community with its valuable contributions, ultimately empowering researchers, professionals, and students engaged in the fight against cancer.

Blood and Lymphatic Cancer-Targets and Therapy

Transforming Cancer Treatment Through Open Access
Publisher: DOVE MEDICAL PRESS LTDISSN: 1179-9889Frequency: 1 issue/year

Blood and Lymphatic Cancer-Targets and Therapy, published by DOVE MEDICAL PRESS LTD, is a vital open-access journal that has been disseminating crucial research and findings in the field of hematology and oncology since 2011. With its ISSN 1179-9889, this journal focuses on the latest therapeutic targets and innovative treatment strategies for blood and lymphatic cancers, contributing significantly to the advancement of knowledge and practice in this specialized area. Designed for researchers, healthcare professionals, and students alike, Blood and Lymphatic Cancer-Targets and Therapy aims to foster a deeper understanding of cancer biology and promote collaborative efforts leading to novel therapeutic interventions. The open-access model ensures that research findings are readily accessible to a global audience, underscoring the journal's commitment to enhancing patient care and fostering educational growth in the cancer domain.